Kodiak Sciences Inc (KOD)
2.935
-0.08
(-2.49%)
USD |
NASDAQ |
May 29, 14:56
Kodiak Sciences SG&A Expense (Quarterly): 16.12M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 16.12M |
| December 31, 2023 | 16.74M |
| September 30, 2023 | 18.31M |
| June 30, 2023 | 17.87M |
| March 31, 2023 | 18.10M |
| December 31, 2022 | 18.07M |
| September 30, 2022 | 17.80M |
| June 30, 2022 | 18.32M |
| March 31, 2022 | 19.59M |
| December 31, 2021 | 17.45M |
| September 30, 2021 | 11.53M |
| June 30, 2021 | 10.50M |
| March 31, 2021 | 10.22M |
| December 31, 2020 | 9.486M |
| Date | Value |
|---|---|
| September 30, 2020 | 7.357M |
| June 30, 2020 | 6.222M |
| March 31, 2020 | 5.553M |
| December 31, 2019 | 3.354M |
| September 30, 2019 | 2.617M |
| June 30, 2019 | 2.976M |
| March 31, 2019 | 2.737M |
| December 31, 2018 | 2.506M |
| September 30, 2018 | 1.671M |
| June 30, 2018 | 1.499M |
| March 31, 2018 | 1.905M |
| December 31, 2017 | 0.982M |
| September 30, 2017 | 0.831M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
2.617M
Minimum
Sep 2019
19.59M
Maximum
Mar 2022
12.41M
Average
13.83M
Median
SG&A Expense (Quarterly) Benchmarks
| Avalo Therapeutics Inc | 3.193M |
| Regeneron Pharmaceuticals Inc | 689.00M |
| Ligand Pharmaceuticals Inc | 10.95M |
| iBio Inc | 2.722M |
| Dare Bioscience Inc | 2.703M |